Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Metastatic or Recurrent Esophageal and GE Junction Cancer
NCT00917462Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2009
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in esophageal cancer, gastroesophageal junction cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2009; status: completed.
02
Drugs
sorafenib
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00917462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00917462.